Sara Brittingham

Downregulation of endogenous TRAIL and its effect on cancer cells

An experimental study

• Broschiertes Buch

Produktbeschreibung

Clinical studies report that increased expression of endogenous tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is associated with decreased disease-specific survival in cancers which are resistant to TRAIL induced apoptosis. The present work investigated the role of endogenous TRAIL as an intrinsic growth factor in apoptosis-resistant human cancer cells. This less-well known effect of TRAIL was studied in the neuroblastoma cell line KELLY, a cancer cell line with intrinsic resistance to TRAIL-induced apoptosis. The functional impact of the knockdown of endogenous TRAIL was investigated by measuring cell growth and cell death after transfection: Interestingly, KELLY cells unexpectedly showed markedly reduced cell growth upon knockdown of endogenous TRAIL. Furthermore, knockdown of TRAIL induced cell death in KELLY cells, which was dependent on caspase-signaling and rescued by the addition of soluble TRAIL. Thus, the present work provided first evidence that endogenous TRAIL functions as an intrinsic survival and growth factor in KELLY cells and supports the potential of endogenous TRAIL to function as a novel therapeutic target in cancer therapy.

Produktdetails

• Verlag: Südwestdeutscher Verlag für Hochschulschriften
• Aufl.
• Seitenzahl: 84
• Erscheinungstermin: 2. Februar 2012
• Englisch
• Abmessung: 220mm x 150mm x 6mm
• Gewicht: 129g
• ISBN-13: 9783838131054
• ISBN-10: 3838131053
• Artikelnr.: 35002505

Autorenporträt

born in Warsaw 1982, she studied Medicine at the TU Munich from 2003-2010. Clinical electives at Johns Hopkins University in Baltimore and New York Presbyterian Hospital were followed by research in the department of gene vectors at the German Research Center for Environmental Health. Since 2011 physician at Bern University Hospital in Switzerland.